AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Marinus PharmaceuticalsSpero TherapeuticsChiasmaEndonovo TherapeuticsTheratechnologies
SymbolNASDAQ:MRNSNASDAQ:SPRONASDAQ:CHMAOTCMKTS:ENDVOTCMKTS:THERF
Price Information
Current Price$2.57$13.00$6.12$0.15$1.80
52 Week RangeBuyBuyBuyN/AHold
Beat the Market™ Rank
Overall Score1.51.51.50.41.1
Analysis Score3.43.53.50.03.0
Community Score2.72.62.52.12.4
Dividend Score0.00.00.00.00.0
Ownership Score1.01.01.00.00.0
Earnings & Valuation Score0.60.60.60.00.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyN/AHold
Consensus Price Target$4.87$23.00$13.00N/A$6.00
% Upside from Price Target89.36% upside76.92% upside112.42% upsideN/A233.33% upside
Trade Information
Market Cap$225.50 million$243.44 million$264.55 million$157.40 million$117.73 million
Beta2.151.961.522.120.58
Average Volume1,071,459131,930354,315148,36025,677
Sales & Book Value
Annual RevenueN/A$18.15 millionN/A$80,000.00$45.18 million
Price / SalesN/A14.75N/A1,878.533.07
CashflowN/AN/AN/AN/A$0.01 per share
Price / CashN/AN/AN/AN/A177.07
Book Value$0.72 per share$3.90 per share$2.04 per share($0.03) per share$0.47 per share
Price / BookN/A3.33N/A-5.003.83
Profitability
Net Income$-54,120,000.00$-60,920,000.00$-36,320,000.00$-6,440,000.00$-4,660,000.00
EPS($0.99)($3.35)($1.06)N/AN/A
Trailing P/E RatioN/AN/AN/A0.000.00
Forward P/E RatioN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-654.03%N/A-5,033.33%-11.57%
Return on Equity (ROE)-131.58%-88.22%-56.26%N/A-14.31%
Return on Assets (ROA)-83.72%-70.36%-48.67%-264.21%-4.25%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.05%N/AN/A1.70%
Current Ratio7.75%4.31%6.28%N/A2.69%
Quick Ratio7.75%4.31%6.28%N/A2.19%
Ownership Information
Institutional Ownership Percentage81.89%52.88%75.24%N/A1.37%
Insider Ownership Percentage2.40%18.34%5.50%5.61%N/A
Miscellaneous
Employees285749N/A32
Shares Outstanding86.73 million20.60 million42.27 million1.00 billion76.95 million
Next Earnings Date8/13/2020 (Estimated)8/13/2020 (Estimated)8/13/2020 (Estimated)6/29/2020 (Estimated)N/A
OptionableOptionableOptionableNot OptionableNot OptionableNot Optionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.